VRDN

Viridian Therapeutics, Inc. (VRDN) ESG Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Environmental

No material environmental disclosure or sustainability metrics were provided this month.

The company remains pre-profit and R&D-heavy, so near-term environmental footprint is not clearly evidenced by the available financial data.

Social

No material social disclosure or workforce metrics were provided this month.

High R&D intensity and negative operating margins suggest continued dependence on specialized talent, but there is no new evidence of a change in labor or customer-related risk.

Governance

No material governance disclosure or board/ownership updates were provided this month.

The balance sheet remains very liquid with a current ratio of 16.9x, but the company is still loss-making and highly valued on sales, which keeps governance and capital-allocation scrutiny elevated.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Viridian Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →